Phase 2 Data on Provectus's PV-10 for Metastatic Melanoma to Be Presented at Two Upcoming Conferences

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Jun 15, 2011 - Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at two upcoming melanoma conferences.

On June 21, 2011, Dr. Sanjiv Agarwala, Chief of Medical Oncology and Hematology at St. Luke's Hospital and Health Network in Bethlehem, PA and Principal Investigator for our Phase 2 trial site at St. Luke's, will deliver an oral presentation at the 7th EADO (European Association of Dermato-Oncology) Conference in Nantes, France. His presentation, entitled, “Chemoablation of Metastatic Melanoma with Intralesional PV-10,” will begin at 2:20 p.m. local time.

On June 25, 2011, Professor Merrick Ross, M.D. of the MD Anderson Cancer Center in Houston, Texas, will be presenting at the HemOnc Today Conference in New York City. His presentation, entitled “Intralesional Therapy for Systemic Disease: Implications for Success and Failure,” will begin at 2:20 p.m. local time.

Dr. Craig Dees, PhD, CEO of Provectus said, “At each of these conferences, investigators for our PV-10 program will provide further data from the Phase 2 trial of PV-10 for metastatic melanoma. We look forward to the opportunities to present these data to both an international and domestic audience, as we prepare for a multi-center, global Phase 3 trial.”

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed its Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

 

Contact: Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, 866-594-5999 #30
CFO, COO
or
Porter, LeVay & Rose, Inc.
Marlon Nurse, DM, VP – Investor Relations
Bill Gordon, SVP – Media Relations
Phone: 212-564-4700

 

Posted: June 2011

View comments

Hide
(web5)